Organ‐specific endoglin (CD105) expression in the angiogenesis of human cancers
- 10 November 2006
- journal article
- research article
- Published by Wiley in Pathology International
- Vol. 56 (12) , 717-723
Abstract
Some markers of angiogenic endothelial cells are emerging as targets for cancer therapy. The present study compared the expression of CD105 with that of other endothelial markers in cancers from various organs. Surgically resected cancer tissues from 188 patients comprising brain (n = 17), lung (n = 38), breast (n = 30), stomach (n = 30), colon (n = 31), liver (n = 32), and kidney (n = 10) cancers were immunohistochemically analyzed on tissue microarrays using a panel of eight endothelial markers. CD31 was expressed in vascular endothelial cells in cancer lesions as well as in non‐cancerous areas (30–100%) in all core tissue samples. CD105 expression was intense and restricted to capillary endothelial cells in cancer lesions (>73%). In contrast, positive expression of CD105 was seen in <20% of non‐cancerous areas in the same organs. However, no significant difference in CD105 expression in vascular endothelial cells between cancer lesions and non‐cancerous areas from liver and renal cancer samples was found. Vascular endothelial growth factor (VEGF), Flt1, and Flk1 were also expressed, but only sporadically and in few samples (<30%), and transforming growth factor (TGF)‐β1 and TGF‐βRII were negative in vascular endothelial cells but generally positive in cancer cells. CD44 was strongly expressed in sinusoidal endothelial cells of the liver (90–100%). These results show that CD105 is expressed specifically in the tumor angiogenesis of brain, lung, breast, stomach, and colon cancers.Keywords
This publication has 28 references indexed in Scilit:
- Endoglin (CD105) is a target for an oral DNA vaccine against breast cancerCancer Immunology, Immunotherapy, 2006
- Endoglin (CD105) expression in human renal cell carcinomaBJU International, 2006
- Role of Serum Vascular Endothelial Growth Factor in the Prediction of Angiogenesis and Prognosis for Non-small Cell Lung CancerLung, 2005
- DNA Vaccines Suppress Angiogenesis and Protect Against Growth of Breast Cancer MetastasesBreast Disease, 2004
- Vascular Endothelial Growth Factor and Its Receptor, Flk-1/KDR, Are Cytoprotective in the Extravascular Compartment of the Ovarian FollicleEndocrinology, 2004
- Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumour vessel invasion after radical surgery for IB–IIA non-small cell lung cancerJournal of Clinical Pathology, 2004
- Correlation between apoptotic index and angiogenesis in non-small cell lung cancer: comparison between CD105 and CD34 as a marker of angiogenesisLung Cancer, 2003
- Enhanced expression of transforming growth factor‐β and its type‐I and type‐II receptors in human glioblastomaInternational Journal of Cancer, 1995
- Prognosis and Breast CancerAmerican Journal of Surgical Pathology, 1991
- Tumor Angiogenesis: Therapeutic ImplicationsNew England Journal of Medicine, 1971